Development of New Diabetes Treatment to Start Local Trials
BHR Pharmaceuticals, based in Nuneaton, is developing technology known as FREMS for the management and treatment of diabetic wounds and peripheral neuropathies.
The FREMS (Frequency Rhythmic Electrical Modulation System) device uses modulated frequency pulses to improve the supply of oxygen to nerve cells with the aim of reducing pain.
Using specialist NHS staff BHR will undertake pilot clinical trials at the George Eliot Hospital in Nuneaton in order to generate evidence to push for further multi centre trials across the NHS and ultimately see
the technology adopted.
If successful, the use of FREMS could help reduce the financial burden the NHS experiences dealing with diabetic conditions and also provide a non-invasive approach that helps provide pain relief without the need for drug treatment and prevent further debilitating illnesses associated with diabetes.
Bharat Vadukul, Director, BHR said: “The main treatments for painful diabetic neuropathy remain management of the underlying diabetes and drugs for the relief of pain. “Despite the significant individual
and social burden associated with diabetic neuropathy, treatment remains unsatisfactory. “There are currently no FDAapproved therapies for diabetic neuropathy so our aim is to work to that and provide a treatment that isclinically proven and works.”
BHR was referred to Coventry City Council by the University of Warwick Science Park’s Business Ready programme. The Council awarded a grant under the Coventry & Warwickshire Innovation Programme which is part funded by the European Regional Development Fund.
Richard Middleton, Innovation Development Officer, Coventry City Council said: “The work BHR are doing could bring about the introduction of an exciting new emerging medical technology to the NHS that could bring cost savings and better outcomes for patients.“Our grant funding will help BHR undertake pilot clinical trials in Coventry & Warwickshire that should provide further evidence to support the case for the NHS to adopt the technology. The results of the trials should generate interest from specialists in the clinical community.”
The Coventry & Warwickshire Innovation Programme supports local SMEs to develop innovative products and services which are new to the market. If you are interested in the programme please email us at: innovation@coventry.gov.uk